No. Plus they are currently focusing on TDT and SCD, both early stage, and both indications becoming more crowed. Also, CRSP should get FDA and EMA approvals for exa-cel in those indications and should have at least five years head start over others.
If the clinical data they present in April/May is good, I expect the SP will increase, but not as high as this. They (DTIL) will also have an upcoming R&D Day (focusing on in vivo programs) mid-year.
There are a number of differences. One example, DTIL have yet to show they can do in vivo editing in humans. Another, both have broad plans for in vivo programs, but delivery outside the liver (using current AAVs for many indications) can be problematic.
Recent EDIT News
- Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting • GlobeNewswire Inc. • 04/22/2024 08:31:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:06:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:03:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:00:16 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 12:54:42 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 10:58:52 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 02/28/2024 10:13:50 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/28/2024 09:39:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 12:06:57 PM
- Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates • GlobeNewswire Inc. • 02/28/2024 12:00:00 PM
- Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events • GlobeNewswire Inc. • 02/21/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:40:25 PM
- Editas Medicine to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 01/31/2024 02:00:00 PM
- Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/08/2024 01:15:00 PM
- Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update • Dow Jones News • 12/13/2023 05:48:00 PM
- Editas Medicine Strikes License Deal With Vertex Pharmaceuticals • Dow Jones News • 12/13/2023 02:49:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:02:25 PM
- Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9 • GlobeNewswire Inc. • 12/13/2023 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:23:53 PM
- Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar • GlobeNewswire Inc. • 12/11/2023 05:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/07/2023 09:30:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:10:40 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM